ALK dreams big in the US, but patients stayed away during corona-struck quarter: "Zero – as in zero – patients went to the doctor's in the first 6-7 weeks"

The Covid-19 outbreak provides some significant challenges for allergy company ALK, especially on the US market, where the company has placed its bets in recent years. This prompts CEO Carsten Hellmann to give up a goal of 10 percent growth in the US in 2020.

Carsten Hellmann, CEO, ALK Photo: ALK / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles